Cargando…

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir

BACKGROUND: Abacavir has been associated with an increased risk of acute myocardial infarction, but the pathogenic mechanisms remain unknown. We evaluated longitudinal changes in pro-atherosclerotic biomarkers in patients initiating abacavir or tenofovir. METHODS: Consecutive patients initiating ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padilla, Authors: Sergio, Masiá, Mar, García, Natalia, Jarrin, Inmaculada, Tormo, Consuelo, Gutiérrez, Félix
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042932/ https://www.ncbi.nlm.nih.gov/pubmed/21294867 http://dx.doi.org/10.1186/1471-2334-11-40

Ejemplares similares

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
por: Dorjee, Kunchok, et al.
Publicado: (2021)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection
por: Nishijima, Takeshi, et al.
Publicado: (2012)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study
por: Masiá, Mar, et al.
Publicado: (2016)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
por: Podzamczer, D, et al.
Publicado: (2021)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
por: Francisci, D, et al.
Publicado: (2010)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy
por: Palacios, R, et al.
Publicado: (2010)

Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV
por: Martinez, Claudia A., et al.
Publicado: (2022)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Martin, Allison, et al.
Publicado: (2011)

Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
por: Arae, Hirotaka, et al.
Publicado: (2016)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial
por: Rasmussen, Thomas A., et al.
Publicado: (2012)

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

937. Virally Suppressed PLH Switching From Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation
por: Funderburg, Nicholas, et al.
Publicado: (2018)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
por: Alzate Angel, Juan Carlos, et al.
Publicado: (2017)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
por: Bhatti, L, et al.
Publicado: (2010)

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
por: Ross, L. L., et al.
Publicado: (2010)

Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience
por: Chin, Bum Sik, et al.
Publicado: (2020)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

1614. Efficacy and Safety of Adjusted Renal Dosing of Tenofovir DF Versus Abacavir Switching in HIV Patients with Decreased Glomerular Filtration Rate After Receiving Tenofovir DF-Based Regimen
por: Yamasmith, Eakkawit, et al.
Publicado: (2023)

Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy
por: Galdamez, Ronald, et al.
Publicado: (2019)

Molecular Recognition of the Antiretroviral Drug Abacavir: Towards the Development of a Novel Carbazole-Based Fluorosensor
por: Idzik, Krzysztof Ryszard, et al.
Publicado: (2011)

Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study
por: Masiá, Mar, et al.
Publicado: (2011)

Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study
por: Masiá, Mar, et al.
Publicado: (2021)

HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
por: Estrada, Vicente, et al.
Publicado: (2022)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_87h1426ejhq46dbdjk33vj8l3t